ClinicalTrials.gg

Program

retlirafusp alfa

Also written as “SHR-1701”, “SHR-1701;BP102” and “SHR-A1811 and SHR-1701”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Nasopharyngeal Carcinoma · Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jun 29, 202120 company-led studies, 6 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine206 open or runningphase 3since Jun 29, 2021Oct 14, 2018Jul 30, 2027phase 2 · NCT05503888

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Oct 14, 2018.

  1. Sep 28, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04580498 · 107 enrolled · China
  2. Nov 2, 20202 phase 2 studiesNCT04624217, NCT04650633
  3. Jan 5, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04699968
  4. Apr 19, 2021Phase 2 study in Advanced Solid TumorsNCT04856774 · 81 enrolled · China
  5. May 7, 2021Phase 2 study in Lung NeoplasmsNCT04884009 · 106 enrolled
  6. Jun 29, 2021Phase 3 study in Gastric or Gastroesophageal Junction CancerNCT04950322 · 737 enrolled · China
  7. Jul 16, 2021Phase 2 study in Advanced or Metastatic Non-squamous Non-small Cell Lung CancerNCT04974957 · 71 enrolled
  8. Aug 23, 2021Phase 2 study in Nasopharyngeal CarcinomaNCT05020925 · 30 enrolled · China
  9. Nov 9, 20212 phase 3 studiesNCT05149807, NCT05132413
  10. Jan 3, 2022Phase 1 study in Advanced Malignant TumorsNCT05198817 · 240 enrolled · China
  11. Mar 18, 2022Phase 2 study in Locally Advanced Rectal CancerNCT05300269 · 73 planned · China
  12. Aug 8, 2022Phase 2 study in RecurrenceNCT05503888 · 160 planned
  13. Jan 3, 2023Phase 2 study in HER2 Expression Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNCT05671822 · 258 planned · China
  14. Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220 · 200 planned · China

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in RecurrenceNCT05503888
  2. Dec 2027Primary completion: phase 2 study in HER2 Expression Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNCT05671822
  3. Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220

TargetBeta

CD274 →TGFB1 →read by rule
“A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) monoclonal antibody bound, via the C-terminal ends of the Fc region, to the N-terminal-truncated extracellular domain (ECD) of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), ”NCIt, by rule

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07175220Carcinoma, Non-Small-Cell Lung · China2RecruitingOct 2028200
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China2RecruitingDec 2027258
NCT05503888Recurrence2Not yet recruitingJul 30, 2027160
NCT05300269Locally Advanced Rectal Cancer · China2RecruitingJul 31, 202473
NCT05198817Advanced Malignant Tumors · China1UNKNOWNJan 31, 2023240
NCT05132413Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer3UNKNOWNDec 30, 2024561
NCT05149807Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer · China3TerminatedApr 3, 202481
NCT05020925Nasopharyngeal Carcinoma · China2UNKNOWNMay 202230
NCT04974957Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer2UNKNOWNFeb 28, 202271
NCT04950322Gastric or Gastroesophageal Junction Cancer · China3Active, not recruitingMay 20, 2024737
NCT04884009Lung Neoplasms2UNKNOWNDec 31, 2022106
NCT04856774Advanced Solid Tumors · China2CompletedMar 30, 202481
NCT04699968Carcinoma, Non-Small-Cell Lung2WithdrawnNov 15, 20210
NCT04650633Squamous Cell Carcinoma of Head and Neck · China2UNKNOWNJan 2023130
NCT04624217Pancreatic Neoplasms · China2CompletedSep 16, 202156
NCT04580498Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingJul 15, 2023107
NCT04282070Nasopharyngeal Carcinoma · China1UNKNOWNApr 16, 202291
NCT04324814Advanced Solid Tumor · Australia1CompletedFeb 1, 202341
NCT03774979Neoplasm Metastasis · China1UNKNOWNMar 2023193
NCT03710265Neoplasm Metastasis · China1UNKNOWNDec 31, 2022206

How it is read

Names in the registry

  • “SHR-1701”, 10 entries
  • “SHR-1701;BP102”, 2 entries
  • “SHR-A1811 and SHR-1701”, 1 entry
  • “SHR-A181, SHR-1701, and capecitabine”, 1 entry
  • “SHR2554; SHR-1701”, 1 entry

Codes read as this program: SHR1701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.